Literature DB >> 28786861

Renal artery stenosis and left ventricular hypertrophy: an updated review and meta-analysis of echocardiographic studies.

Cesare Cuspidi1, Raffaella Dell'Oro, Carla Sala, Marijana Tadic, Elisa Gherbesi, Guido Grassi, Giuseppe Mancia.   

Abstract

AIM: Data on left ventricular hypertrophy (LVH) in patients with renal artery stenosis (RAS) and its regression following renal revascularization are scanty. We performed a meta-analysis to provide comprehensive information on this clinically relevant issue.
METHODS: Full articles providing data on: LVH, as assessed by echocardiography, in RAS patients as compared with essential hypertensive counterparts; changes of left ventricular (LV) mass index after renal artery revascularization were considered.
RESULTS: A total of 905 study participants (RAS = 446, essential hypertensive = 459) of both sex were included in nine studies. Pooled LV mass index was higher in RAS than in essential hypertensive patients (140.4 ± 11.1 g/m versus 121.8 ± 6.2 g/m, standard mean difference being 0.41 ± 0.07 [95% confidence interval (CI) 0.27-0.51, P < 0.001]. Among 360 RAS patients undergone renal revascularization from eight studies, baseline and post-intervention pooled mean LV mass index values were 129.0 ± 10.2 g/m and 115.5 ± 9.9 g/m, respectively, the standard mean difference being-0.36 ± 0.06 (95% CI from -0.47 to -0.25, P < 0.001). These findings were unaffected by publication bias or single study effect.
CONCLUSION: Our meta-analysis indicates that RAS patients have an increased likelihood of LVH compared with essential hypertensive counterparts and renal artery revascularization has a beneficial effect on LV structure, as reflected by a significant decrease in LV mass index.

Entities:  

Mesh:

Year:  2017        PMID: 28786861     DOI: 10.1097/HJH.0000000000001500

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  4 in total

Review 1.  How should we define appropriate patients for percutaneous transluminal renal angioplasty treatment?

Authors:  Yoshio Iwashima; Toshihiko Ishimitsu
Journal:  Hypertens Res       Date:  2020-06-22       Impact factor: 3.872

Review 2.  Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia.

Authors:  Alexandre Persu; Piotr Dobrowolski; Heather L Gornik; Jeffrey W Olin; David Adlam; Michel Azizi; Pierre Boutouyrie; Rosa Maria Bruno; Marion Boulanger; Jean-Baptiste Demoulin; Santhi K Ganesh; Tomasz J Guzik; Magdalena Januszewicz; Jason C Kovacic; Mariusz Kruk; Peter de Leeuw; Bart L Loeys; Marco Pappaccogli; Melanie H A M Perik; Emmanuel Touzé; Patricia Van der Niepen; Daan J L Van Twist; Ewa Warchoł-Celińska; Aleksander Prejbisz; Andrzej Januszewicz
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

3.  High renin hypertension in focal renal fibromuscular dysplasia: turn off of renin system angiotensin overactivation by renal angioplasty cured high blood pressure and quickly reversed myocardial hypertrophy.

Authors:  Simona Merla; Riccardo Simoni; Stefano Tedeschi; Massimiliano Ferrari; Giovanni Passeri; Carla Marcato; Enrico Epifani; Ignazio Semproni; Giulia Zini; Ignazio Verzicco; Pietro Coghi; Riccardo Volpi; Aderville Cabassi
Journal:  Acta Biomed       Date:  2021-04-30

4.  Cardiac function response to stenting in atherosclerotic renal artery disease with and without heart failure: results from the Carmel study.

Authors:  Osami Kawarada; Teruyoshi Kume; Kan Zen; Shigeru Nakamura; Koji Hozawa; Tadafumi Akimitsu; Hiroshi Asano; Hiroshi Ando; Yoshito Yamamoto; Takehiro Yamashita; Norihiko Shinozaki; Keita Odashiro; Tadaya Sato; Kenichiro Yuba; Yuji Sakanoue; Takashi Uzu; Kozo Okada; Peter J Fitzgerald; Yasuhiro Honda; Satoshi Yasuda
Journal:  ESC Heart Fail       Date:  2019-01-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.